FlowCardia, Inc. Appoints Deborah DeFilippo CFO - Gilde Healthcare

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

18 June 2008

SUNNYVALE, Calif., June 18, 2008 — FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer. Ms. DeFilippo comes to FlowCardia with over 19 years of experience in Medical Devices. 

Most recently, Ms. DeFilippo served as Chief Financial Officer and Vice President, Business Development for the Guidant Cardiac Surgery business. Prior to that, she held a variety of executive positions at Guidant divisions as well as the Corporate Office of Guidant. Earlier, Ms. DeFilippo was the Director of Finance and Information Systems at Devices for Vascular Intervention prior to DVI’s acquisition by Guidant. Ms. DeFilippo holds a B.A. from Stanford University.

“We are tremendously pleased that Deborah will be joining FlowCardia. She is not only a very experienced financial executive but has also overseen such functions as Strategic Planning, Information Systems and Business Reengineering during her time with Guidant,”

said Wick Goodspeed, President and CEO of FlowCardia.

“Deborah will be a great addition to our management team and a substantial contributor to our sales growth and transition to profitability over the next few years.”

“I’m thrilled to be returning to the medical device field and joining FlowCardia at such an exciting time,”

said Ms. DeFilippo.

“FlowCardia is growing rapidly in its first year of commercialization and I am enthusiastic about the opportunity to help the Company become the leading CTO Device Company in the world.”

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture endovascular CTO recanalization systems. Additional information is available on the Company’s Web Site at www.flowcardia.com.

CONTACT
Mark Page
Sr. Director Marketing
FlowCardia, Inc.
T: 408-617-0352 ext. 301

SOURCE
FlowCardia, Inc.

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021